Sanofi (SNY) Given Consensus Rating of “Hold” by Analysts
Sanofi (NYSE:SNY) has earned a consensus recommendation of “Hold” from the fourteen brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $53.50.
SNY has been the subject of several recent analyst reports. Cowen Inc reaffirmed a “market perform” rating and issued a $52.00 target price (up from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. BidaskClub raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. raised shares of Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. Argus reaffirmed a “buy” rating and issued a $55.00 target price on shares of Sanofi in a report on Friday, September 1st. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a report on Friday, September 15th.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SNY. Bank of Nova Scotia Trust Co. purchased a new position in shares of Sanofi during the third quarter valued at approximately $125,000. Parallel Advisors LLC raised its holdings in shares of Sanofi by 42.5% during the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after purchasing an additional 875 shares during the last quarter. YorkBridge Wealth Partners LLC raised its holdings in shares of Sanofi by 33.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after purchasing an additional 776 shares during the last quarter. Eagle Ridge Investment Management purchased a new position in shares of Sanofi during the second quarter valued at approximately $160,000. Finally, Bronfman E.L. Rothschild L.P. raised its holdings in shares of Sanofi by 142.8% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after purchasing an additional 2,098 shares during the last quarter. 9.30% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/11/24/sanofi-sny-given-consensus-rating-of-hold-by-analysts.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.